| Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. | skin, |
| Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset. | thyroid, |
| MITF-BCL2A1 as a lineage-specific oncogenic pathway in melanoma and underscore its role for improved response to BRAF-directed therapy. | skin, |
| Antitumor effects of vemurafenib are mediated by inhibiting oncogenic MAPK signaling in BRAF(V600)-mutant metastatic melanoma. Data suggest that inhibition downstream of BRAF should help to overcome acquired resistance. | skin, |
| Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. | skin, |
| Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. | skin, |
| Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. | skin, |
| Contribution of the BRAF oncogene in the pre-operative phase of thyroid carcinoma. | thyroid, |
| High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFbeta in thyroid follicular cells. | thyroid, |
| Response to vemurafenib suggests that BRAFV600 is an oncogenic driver in pediatric gliomas. | pediatric,glioma, |
| Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. | lung, |
| Data indicate mutation in the proto-oncogene protein B-raf (BRAF) gene at the time of hairy cell leukemia (HCL) diagnosis in two cases. | leukemia, |
| Data suggest that proto-oncogene potein B-raf (BRAF) V600E mutations are present in rare cases of dendritic cell and histiocytic disorders, and their identifi cation off ers a potential therapeutic target for these neoplasms. | neoplasm, |
| miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. | skin, |
| V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. | sarcoma, |
| Proto-Oncogene Proteins B-raf V600E mutation analysis is considered to be the most useful diagnostic tool for differentiating hairy cell leukemia from related lymphomas. | lymphoma,leukemia, |
| Report increased frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran. | colorectal, |
| High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran. | colorectal, |
| Results indicated that rs3748093*A single nucleotide polymorphisms (SNPs) of BRAF proto-oncogene (BRAF) was significantly correlated with an increased risk of papillary thyroid carcinoma (PTC) in a Chinese population. | thyroid, |
| We show for the first time that this important pediatric tumor may harbor the oncogenic BRAFV600E mutation, providing the first insights to their personalized treatment. | pediatric, |